People · Operator
Named in public records as an officer, director or promoter · active 2020–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aro Biotherapeutics Co | — | Pharmaceuticals | Series C | $122.9M | $360.3M | 2020 |
Christopher B Mirabelli at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher B Mirabelli on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Susan B Dillon | 1 | 1 |
| Scott B Greenberg | 1 | 1 |
| Karyn B O'Neil | 1 | 1 |
| Marten B Steen | 1 | 1 |
| Bruce B Peacock | 1 | 1 |
| Elizabeth B Anderson | 1 | 1 |
| Daniel B Janse | 1 | 1 |
| Mark B Laurenzi | 1 | 1 |
| Kevin B Raidy | 1 | 1 |
| Mittie B Doyle | 1 | 1 |
| Jess B Lifton | 1 | 1 |
| Saan-Chirag B Gandhi | 1 | 1 |
| Mark V. Laurenzi | 1 | 1 |
| Elizabeth V. Anderson | 1 | 1 |
| Bruce V. Peacock | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.